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162The effect of extremity vascular complications on
the outcomes of cardiac support device recipients
J. Westley Ohman, MD,a Chandu Vemuri, MD,a Sunil Prasad, MD,b Scott C. Silvestry, MD,b
Jeffrey Jim, MD, MPHS,a and Patrick J. Geraghty, MD,a St. Louis, Mo
Objective: To assess the effect of extremity vascular complications (EVCs, including ischemia or vessel trauma) on the
outcomes of patients receiving cardiac support devices (CSDs, including ventricular assist device [VAD] and extra-
corporeal membrane oxygenation [ECMO]).
Methods: Institutional Review Board-approved, retrospective review of a prospectively maintained database of all tem-
porary and permanent CSD recipients from 7/1/10 to 6/30/12. Patient demographics, procedural data, and outcomes
were analyzed. The primary endpoint was all-cause mortality at 30-days post-CSD initiation.
Results: Of 208 patients who received CSDs, 31 (14.9%) experienced EVC: 13 (8.9%) of the 146 permanent VADs, 10
(26.3%) of the 38 temporary VADs, and 8 (33.3%) of the 24 ECMO patients. The 30-day mortality for CSD-EVC
patients was not signiﬁcantly higher than that of the CSD patients who did not experience EVC for permanent VAD
(15.4% vs 4.5%; P[ .15) and ECMO patients (50.0% vs 68.75%; P[ 1.00), but was signiﬁcantly higher for temporary
VAD patients (80.0% vs 35.7%; P [ .03). Within the CSD-EVC cohort, patients who received a temporary VAD had a
signiﬁcantly higher 30-day mortality and decision to withdraw care after EVC compared with those who received a
permanent VAD (P [ .01 and P < .01, respectively). Looking beyond the 30-day window, EVC was associated with
higher mortality rates in the permanent VAD population (53.8% vs 25.6%; P [ .025) but not the temporary VAD or
ECMO groups.
Conclusions: In temporary VAD recipients, EVCs result in higher 30-day mortality, more frequent withdrawal of care, and
shortened survival time relative to the global temporary VAD group. EVC in permanent VAD recipients did not affect
early (30-day) mortality rates, but strongly predicted a higher cumulative mortality risk for the 2-year study period.
Overall ECMO mortality rates were high, and not signiﬁcantly impacted by the occurrence of EVC. The nature of the
EVC (cannulation site complication vs embolic injury) did not impact mortality. This data provides quality improvement
targets for VAD programs. (J Vasc Surg 2014;59:1622-7.)Cardiac support devices (CSDs) have revolutionized
the way heart failure is managed in the United States and
Europe. Over 6000 patients have received a ventricular
assist device (VAD) since 2006,1 with 1-year survival rates
exceeding 80%1 and 1-year freedom from major events
rates of 30%.1 Extracorporeal membrane oxygenation
(ECMO) has been in use since 19712 for several indica-
tions. In each class of CSD, the option for peripheral can-
nulation via the femoral or axillary artery can be achieved
by either an open or percutaneous approach. The risk of
early and late arterial injuries as a consequence of ECMO
cannulation has been reported to be as high as 28%,2-8
and adjuvant techniques have been employed to mitigate
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2EVCs following VAD implantation can arise from arte-
rial cannulation site complications, as well as thromboem-
bolic events from the devices themselves. Early VADs were
associated with a nearly 33% risk of thromboembolic
events9; however, recent advances in device design and
materials have decreased that risk signiﬁcantly, with pub-
lished case series reﬂecting thromboembolism rates of 2%
to 6%.9-11
As one of the highest volume VAD implantation cen-
ters in the country, we reviewed our experience in the chal-
lenging management of patients who develop EVCs while
being maintained on a CSD.
METHODS
Identiﬁcation of patients. A retrospective chart
review of a prospectively maintained database on all tem-
porary and permanent CSD patients from 7/1/2010 to
6/30/2012 at a single institution was performed.
ECMO patients were prospectively enrolled in this data-
base after 7/1/2011. For patients who had been placed
on ECMO between 7/1/2010 and 7/1/2011, a retro-
spective chart review was undertaken for all study variables.
Demographic data, procedural information, device infor-
mation, and patient outcomes data were analyzed. Vascular
surgery consultation was determined based on the presence
of a documented vascular surgery consultation form, or a
dictated operative note by a staff vascular surgeon docu-
menting an EVC related to the CSD.
Table I. Preoperative demographic information of all
three device categories
Non-EVC EVC P value
Temporary 28 10
Permanent 133 13
ECMO 16 8
Age, years
Temporary 51.43 6 2.58 51.00 6 4.67 .9340
Permanent 55.65 6 1.08 47.31 6 4.56 .0274
ECMO 52.63 6 3.04 54.38 6 5.43 .7632
Male
Temporary 22 (78.6) 8 (80.0) 1.0000
Permanent 110 (82.7) 9 (69.2) .2611
ECMO 12 (75.0) 5 (62.5) .6466
Nonwhite
Temporary 8 (28.6) 0 (0.0) .0821
Permanent 34 (25.6) 1 (7.7) .1907
ECMO 5 (31.3) 3 (37.5) 1.0000
Smoking
Temporary 5 (17.9) 2 (20.0) 1.0000
Permanent 27 (20.3) 4 (30.8) .4751
ECMO 3 (18.8) 2 (25.0) 1.0000
Diabetes mellitus
Temporary 10 (35.7) 4 (40.0) 1.0000
Permanent 66 (49.6) 7 (53.8) 1.0000
ECMO 5 (31.3) 4 (50.0) 1.0000
Renal failure
Temporary 18 (64.3) 5 (50.0) .4726
Permanent 58 (43.9) 4 (30.8) .5642
ECMO 8 (50.0) 0 (0.0) .0222
Hypertension
Temporary 21 (75.0) 6 (60.0) .4318
Permanent 101 (75.9) 6 (46.2) .0423
ECMO 10 (62.5) 6 (75.0) .6674
Peripheral arterial disease
Temporary 5 (17.9) 2 (20.0) 1.0000
Permanent 32 (24.1) 2 (15.4) .7331
ECMO 5 (31.3) 1 (12.5) .6214
Cardiogenic shock
Temporary 21 (75.0) 10 (100.0) .1564
Permanent 59 (44.4) 9 (69.2) .1431
ECMO 2 (25.0) 2 (12.5) .5784
ECMO, Extracorporal membraneous oxygenation; EVC, extremity vascular
complication.
Continuous data are presented as mean 6 standard error of the mean and
categoric data as number (%).
Table II. Surgical outcome data for all three subgroups
based on intervention offered
Permanent
VAD, No. (%)
Temporary
VAD, No. (%)
ECMO,
No. (%)
CSD recipients
experiencing EVC
13 10 8
Outcomes
No intervention
offered
4 (30.8) 1 (10.0) 2 (25.0)
Observation 2 (15.4) 0 (0.0) 0 (0.0)
Any vascular
procedure
7 (53.9) 9 (90.0) 6 (75.0)
Revascularization 5 (38.5) 4 (40.0) 2 (25.0)
Amputation 0 (0.0) 1 (10.0) 1 (12.5)
CSD, Cardiac support device; ECMO, extracorporeal membrane oxy-
genation; EVC, extremity vascular complications; VAD, ventricular assist
device.
Intergroup comparisons do not reach statistical signiﬁcance of P < .05.
Table III. Mortality outcomes based on complication
type
Embolic, No. (%) Cannulation, No. (%) P value
Events
All 16 (51.6) 15 (48.4)
Temporary 5 (50.0) 5 (50.0)
Permanent 8 (61.5) 5 (38.5)
ECMO 3 (37.5) 5 (62.5)
30-day mortality
All 9/16 (56.3) 5/15 (33.3) .2852
Temporary 4/5 (80.0) 4/5 (80.0) 1.0000
Permanent 2/8 (25.0) 0/5 (0.0) .4872
ECMO 3/3 (100.0) 1/5 (20.0) .1429
2-year mortality
All 12/16 (75.0) 8/15 (53.3) .2734
Temporary 4/5 (80.0) 4/5 (80.0) 1.0000
Permanent 5/8 (62.5) 2/5 (40.0) .5921
ECMO 3/3 (100.0) 2/5 (40.0) .1964
ECMO, Extracorporeal membrane oxygenation.
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Volume 59, Number 6 Ohman et al 1623Device classiﬁcation. The following CSDs were classi-
ﬁed as temporary: Abiomed (Danvers, Mass) AB5000,
BVS5000, and all variants of Impella; Jarvik Heart (New
York, NY) Jarvik 2000; and Thoratec (Pleasanton, Calif)
Centrimag. The following devices were classiﬁed as perma-
nent, regardless of bridge-to-transplantation or destination
therapy designations: Thoratec HeartMate II and Ventr-
Assist, and HeartWare (Framingham, Mass) HVAD.
Patient selection. A total of 208 device implantations
were recorded during the timeframe included in the
study. Forty-one of the 208 patients received vascular
surgery consultation. Of those 41 consultations, nine were
excluded from analysis for being unrelated to EVCs (seven
for hemodialysis access, and two for inferior vena cava
ﬁlter placement). The remaining 32 consultations were
conﬁrmed to involve vascular complications involvingthe upper and/or lower extremities, either based on the
vascular interventions performed; or, in the case where
medical futility was documented, based on the ﬁndings
documented in the consultation note. The nature of the
complication was determined by details contained within
the operative or consultation notes. Macroembolic and
microembolic injuries of the lower extremities were
grouped as embolic complications, whereas any cannula-
tion injury was counted as a cannulation complication.
The mean follow-up time for temporary VAD patients
who suffered an EVC was 104 6 26 days, for permanent
VAD patients who suffered an EVC was 261 6 18 days,
and for ECMO patients who suffered an EVC was 72 6
22 days.
Statistical analysis. Statistical analyses were performed
using GraphPad Prism version 6.0 (GraphPad Software,
Inc, La Jolla, Calif). Categorical data were analyzed using
Fisher exact test, and continuous data were analyzed using
Table IV. Overview of complications encountered in patients who received a temporary ventricular assist device (VAD)
Patient Device Complication Intervention Outcome
1 Impella Embolic ischemia BLE R Guillotine through knee, R PFA
thrombectomy, L SFA
thrombectomy, L calf
fasciotomies
Withdrawal of care PCOD4/
PVOD3
2 Abiomed AB5000 Embolic ischemia BLE L femoral-popliteal thrombectomy,
R CFA thrombectomy, R thigh
and calf fasciotomies
Withdrawal of care PCOD6/
PVOD6
3 CentriMag Cannulation RLE Repair of R CFA Withdrawal of care on PCOD13/
PVOD9
4 Abiomed BVS5000 Cannulation LLE/DVT Repair of L CFA & CFV Withdrawal of care on POD17
5 Impella Cannulation LLE Re-do repair of L CFA Withdrawal of care on PCOD18/
PVOD8
6 Abiomed AB5000 Cannulation RLE/DVT R calf fasciotomies Withdrawal of care on POD18
7 CentriMag Embolic ischemia LLE None offered Withdrawal of care on PCOD22
8 Impella Embolic ischemia LLE LLE angiogram, L thigh and calf
fasciotomies
Withdrawal of care PCOD23/
PVOD17
9 CentriMag Cannulation RLE Repair of R CFA Alive at last follow-up PCOD370/
PVOD369
10 Impella Embolic Ischemia RUE R axillosubclavian angiogram,
thrombectomy of R
axillosubclavian artery
Alive at last follow-up PCOD290/
PVOD283
B, Both; CFA, common femoral artery; CFV, common femoral vein; DVT, deep vein thrombosis; L, left; LE, lower extremity; PCOD, post cardiac operative
day; PFA, profunda femoris artery; POD, postoperative day (in cases of same day cardiac and vascular interventions); PVOD, post vascular operative day;
R, right; UE, upper extremity.
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error of the mean. Kaplan-Meier curve signiﬁcance was
determined using the Gehan-Breslow-Wilcoxon test.RESULTS
As Table I shows, patient demographics were similar
between those who suffered an EVC vs those who did
not. Of the 208 patients who received CSDs, 31 (14.9%)
experienced EVCs: 13 (8.9%) of the 146 permanent
VADs, 10 (26.3%) of the 38 temporary VADs, and 8
(33.3%) of the 24 ECMO patients. Permanent VAD
patients who experienced EVCs were younger (47.31 6
4.56 years vs 55.5 6 1.08 years; P ¼ .0274) and less likely
to have a preimplantation diagnosis of hypertension (46.2%
vs 75.9%; P ¼ .423), while ECMO patients who experi-
enced EVCs were less likely to carry a preimplantation diag-
nosis of renal failure (0.0% vs 50.0%; P ¼ .0222). Race,
gender, minority status, smoking, diabetic status, and pre-
existing peripheral arterial disease were not associated
with developing EVCs in any of the three device groups.
Table II details the EVC management undertaken for
each of the patient cohorts. There were no signiﬁcant dif-
ferences in the percentage of patients in each CSD recipient
group who underwent surgical intervention or progressed
to limb loss.
Table III demonstrates the outcomes of complication
type, stratiﬁed by CSD cohort. There was a trend toward
increased 30-day mortality in those patients who suffered
an embolic event relative to a cannulation injury across all
groups (68.8% vs 33.3%; P ¼ .0756) and within the perma-
nent VAD (50.0% vs 0.0%; P ¼ .1049) and the ECMOgroup (100.0% vs 20.0%; P ¼ .1429). This was not seen
in the equal mortality in the temporary VAD group.
Tables IV-VI offer greater detail regarding the
implanted devices, EVC complication type, intervention
undertaken, and clinical outcome for each CSD implant
group.
Thirty-day mortality. The occurrence of EVC did
not signiﬁcantly affect 30-day mortality rates for patients
who received a permanent VAD or ECMO (Table III).
However, those who received a temporary VAD and suf-
fered an EVC were signiﬁcantly more likely to succumb
within 30 days (80.0% vs 35.7%; P ¼ .0265). This was
reﬂected in the increased rate of 30-day withdrawal of care
observed in the temporary VAD patients who suffered an
EVC (80.0% vs 14.3%; P ¼ .0004), a trend not observed in
the permanent VAD or ECMO groups (Table VII).
Cumulative mortality. Looking beyond the 30-day
window, we found that the survival rate of temporary
VAD patients over the entire study period was poor,
but not signiﬁcantly affected by the occurrence of EVC
(P ¼ .3374; Fig 1). To the contrary, permanent VAD
patients who developed an EVC, despite not having a
signiﬁcantly higher 30-day mortality, had a statistically
signiﬁcant increase in overall mortality during the study
period (P ¼ .0074; Fig 2). There was no change in overall
mortality during the study period for patients on ECMO
who developed an EVC (P ¼ .8066; Fig 3).DISCUSSION
Despite improved device design and materials, as well
as increased medical experience with CSDs, extremity
Table V. Overview of complications encountered in patients who received a permanent ventricular assist device (VAD)
Patient Device Complication Intervention Outcome
1 HeartMate II Embolic ischemia LLE Thrombectomy of L SFA,
popliteal, TP trunk, AT, PT,
and peroneal
Withdrawal of care on PCOD34/
PVOD32
2 HeartMate II Embolic ischemia BLE None offered Died on PCOD9
3 HeartMate II Embolic ischemia RUE Thrombectomy of R radial Withdrawal of care on PCOD41/
PVOD36
4 HeartWare HVAD Embolic ischemia BLE None offered Died on PCOD9
5 HeartMate II Cannulation RLE None offered Died on PCOD61
6 HeartMate II Cannulation RLE Repair of L CFA PSA Withdrawal of care on PCOD90/
PVOD32
7 HeartMate II Embolic ischemia RLE None offered Died on PCOD 170
8 HeartMate II Cannulation LLE Repair of L CFA laceration Alive at last follow-up POD556
9 HeartMate II Cannulation RLE R CIA to CFA bypass, ligation
of lacerated R EIA
Alive at last follow-up POD555
10 HeartMate II Micro-embolic Ischemia LLE None offered Alive at last follow-up PCOD443
11 HeartWare HVAD Cannulation LLE Evacuation of L groin
hematoma
Alive at last follow-up PCOD205/
PVOD127
12 HeartMate II Micro-embolic ischemia RLE R SFA athrectomy and R SFA
stent
Alive at last follow-up PCOD127/
PVOD71
13 HeartWare HVAD Embolic ischemia RLE R EIA thrombectomy, R CFA
patch angioplasty
Alive at last follow-up POD45
AT, Anterior tibial; B, both; CFA, common femoral artery; CFV, common femoral vein; CIA, common iliac artery; DVT, deep vein thrombosis; EIA, external
iliac artery; L, left; LE, lower extremity; PCOD, post cardiac operative day; PFA, profunda femoris artery; POD, postoperative day (in cases of same day cardiac
and vascular interventions); PSA, pseudoaneurysm; PT, posterior tibial; PVOD, post vascular operative day; R, right; SFA, superﬁcial femoral artery; TP,
tibioperitoneal; UE, upper extremity.
Table VI. Overview of complications encountered in patients who were placed on extracorporeal membrane
oxygenation (ECMO)
Patient Complication Intervention Outcome
1 Mixed ischemia of LUE, LLE None offered Withdrawal of care on PCOD3 (profound
neurological deﬁcits)
2 Cannulation RLE R CFA endarterectomy and patch
angioplasty
Withdrawal of care on PCOD2/PVOD0 (developed
pulmonary hemorrhage)
3 Embolic ischemia BLE None offered Withdrawal of care on PCOD4 (profound MSOF)
4 Embolic ischemia BLE Bilateral below knee guillotine
amputations for wet gangrene
Withdrawal of care on PCOD28/PVOD9
(MSOF, sepsis)
5 Cannulation LLE Revision of L aortobifemoral graft
limb
Withdrawal of care on POD37 (ischemic hepatitis and
renal failure)
6 Cannulation LLE Repair of L CFA Alive at last follow-up POD269
7 Cannulation RLE Repair of R CFA PSA/R groin
hematoma evacuation
Alive at end of study period PCOD47/PVOD47 and
PVOD19
8 Cannulation RLE Repair of R CFA Alive at end of study period POD28
B, Both; CFA, common femoral artery; L, left; LE, lower extremity; MSOF, multisystem organ failure; PCOD, post cardiac operative day; PFA, profunda
femoris artery; POD, postoperative day (in cases of same day cardiac and vascular interventions); PSA, pseudoaneurysm; PVOD, post vascular operative day; R,
right; UE, upper extremity.
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morbid complication. Overall, 14.9% of CSD patients
developed EVCs during the study period; however, aggres-
sive peri- and postoperative observation allowed for timely
vascular surgery interventions that place our amputation
rate at 6.5% for patients with EVC, and 0.9% of all patients
who undergo placement of a CSD. Our surgical approach
did not substantially vary between CSD groups. The
majority (77.4%) of patients who developed EVC were
offered surgical intervention, with 45.8% of those under-
going a revascularization procedure. Open surgical embo-
lectomy was the standard surgical approach for acute limbischemia, and surgical bypass with artiﬁcial conduit was
used only the in setting of a previous bypass conduit being
accessed (patient 5, ECMO) or profound iliac artery
trauma (patient 9, permanent VAD).
It is interesting to note that neither the usual risk fac-
tors for peripheral arterial disease (including tobacco use
and diabetes) nor a documented prior history of peripheral
arterial disease predicted the development of EVC in any of
the three device groups. Additionally, the presence of
documented cardiogenic shock at the time of implantation
did not vary between the non-EVC and EVC groups in any
device cohort, suggesting that the medical stability of a
Fig 3. Kaplan-Meier survival curve demonstrating the survival
of patients were placed on extracorporal membraneous oxygena-
tion (ECMO) in patients who suffered an extremity vascular
complication (EVC; solid line) compared with those who did not
(dashed line).
Table VII. Mortality outcomes for all three subgroups
Non-EVC,
No. (%)
EVC,
No. (%) P value
30-day mortality
Temporary 10 (35.7) 8 (80.0) .0265
Permanent 6 (4.5) 2 (15.4) .1510
ECMO 11 (68.8) 4 (50.0) .4120
30-day withdrawal of care
Temporary 4 (14.3) 8 (80.0) .0004
Permanent 8 (6.0) 3 (23.1) .0602
ECMO 11 (68.8) 4 (50.0) .4120
ECMO, Extracorporal membraneous oxygenation; EVC, extremity vascular
complication.
All mortality P values were computed using Fisher exact test.
Fig 1. Kaplan-Meier survival curve demonstrating the survival of
patients who received a temporary ventricular assist device (VAD)
in patients who suffered an extremity vascular complication (EVC;
solid line) compared with those who did not (dashed line).
Fig 2. Kaplan-Meier survival curve demonstrating the survival of
patients who received a permanent ventricular assist device (VAD)
in patients who suffered an extremity vascular complication (EVC;
solid line) compared with those who did not (dashed line).
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possible contributors to EVC include cardiogenic throm-
boembolism, device-based thromboembolism, underlying
hypercoagulable and/or coagulopathic states, and possible
technical mishaps.
At our institution, temporary VAD and ECMO
patients are maintained on therapeutic anticoagulation
in form of a heparin (or bivalirudin, in the case of docu-
mented positive heparin-induced thrombocytopenia/
platelet factor-4 assay) bridge to coumadin with an inter-
national normalized ratio of 2 to 3. Our practice is to
maintain permanent VAD patients on therapeutic anti-
coagulation, unless they develop contraindications and
are then transitioned to full-dose aspirin. In the current
series, perievent laboratory analysis shows that all embolic
events happened while patients were therapeutically
anticoagulated.
Our institution aggressively manages cannulation site
complications. There is a low threshold for obtaining
intra- or postimplantation vascular surgery consultation,particularly for cannulation sites that may have accessed
in emergent fashion or in cases where the anatomy has
been distorted by previous interventional or surgical access.
Eight of 15 (53.3%) cannulation consults were obtained
pre- or intraoperatively during the study period, and a
further two (13.3%) were obtained within 7 days of
surgery.
There was no signiﬁcant difference in 30-day mortal-
ity in patients who suffered embolic insult vs a cannula-
tion injury. However, patients who suffered embolic
insults to multiple extremities had a uniformly dire prog-
nosis. This subset of patients frequently incurred
JOURNAL OF VASCULAR SURGERY
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including the cerebral and mesenteric territories. Not
surprisingly, heroic measures such as bilateral lower ex-
tremity thrombectomies and/or amputations (patient 2,
temporary VAD; patient 4, ECMO) did not alter their
dismal course.
The overall survival curves during the study period
show that patients with a temporary VAD who develop
an EVC are not at an increased risk of mortality past the
30-day window. In contrast, our experience shows that pa-
tients with a permanent VAD who develop an EVC are at a
signiﬁcantly higher risk of cumulative mortality. It will be
interesting to see if this ﬁnding is borne out by the ongoing
REVIVE IT (Randomized Evaluation of VAD InterVen-
tion before Inotropic Therapy) Trial. In terms of our
ECMO patient population, there is a high pre-existing
30-day mortality burden (68.8%) consistent with prior
published results,3,7 and our small sample size for this sub-
group in particular may not adequately power this sub-
group analysis.
The externally visible nature of EVC frequently
prompts a critical reassessment of the ongoing viability
of these profoundly ill patients by family members and
the managing heart failure team; thus, vascular surgeons
should seek to deﬁne the prognostic implications of
these events. Our experience suggests several important
points for clinicians. The nature of the type of EVC
did not signiﬁcantly impact 30-day mortality in any of
the three device groups, suggesting that the insult of a
major cannulation site injury is just grave as that of an
embolic event. Simultaneous embolic compromise of
multiple extremities was associated with 100% 30-day
mortality, despite aggressive surgical interventions and
the absence of overt neurologic compromise. Further
investigation of preventative anticoagulation regimes
may lead to reductions in the occurrence and/or
severity of this lethal event. EVCs in temporary VAD re-
cipients sharply increases their 30-day mortality, yet this
difference is lost over the cumulative study period, in
part due to the high cumulative mortality rate in all
temporary VAD recipients. In contrast, the occurrence
of EVC in permanent VAD recipients is a powerful pre-
dictor of increased cumulative mortality rates. Reduction
of cannulation and thromboembolic complications in
elective (permanent) VAD implants should therefore
be a target for outcomes improvement efforts at heart
failure centers.AUTHOR CONTRIBUTIONS
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